Ascendis Pharma A/S (ASND)
| Market Cap | 7.01B |
| Revenue (ttm) | 6.44M |
| Net Income (ttm) | -492.27M |
| Shares Out | 53.83M |
| EPS (ttm) | -9.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $130.25 |
| Previous Close | $128.22 |
| Change ($) | 2.03 |
| Change (%) | 1.58% |
| Day's Open | 127.36 |
| Day's Range | 125.96 - 130.33 |
| Day's Volume | 203,772 |
| 52-Week Range | 119.11 - 183.98 |
Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 Prescription Drug User Fee Act (PDUFA) goal date extended by three months...
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China...
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 0 2 0 1 Indifferent ...
Online event to include a live reading by Children's Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards Online event to include a live reading by Ch...
– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –
COPENHAGEN, Denmark, May 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates tha...
– Marks next step to bring the potential first ever hormone replacement therapy for hypoparathyroidism to Japan – – Marks next step to bring the potential first ever hormone replacement therapy for hypo...
Ascendis Pharma A/S (NASDAQ: ASND) has announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the Phase 2 PaTH Forward Trial evaluating TransCon PTH in adult sub...
– 58 subjects continue in the open-label extension study for TransCon PTH –
COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, t...
COPENHAGEN, Denmark, May 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates tha...
COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs,...
Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum
COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates t...
Clinical data demonstrate the potential of TransCon PTH as a hormone replacement therapy for adults with hypoparathyroidism Clinical data demonstrate the potential of TransCon PTH as a hormone replaceme...
COPENHAGEN, Denmark, March 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates t...
– Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track –
COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs...
On Wednesday, March 10, Ascendis Pharma (NASDAQ:ASND) will release its latest earnings report. Benzinga's outlook for Ascendis Pharma is included in the following report.
COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates t...
COPENHAGEN, Denmark, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, ...
COPENHAGEN, Denmark, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...
If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the chances tha...
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experien...
COPENHAGEN, Denmark, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...
– Advances Vision 3x3 to extend global clinical and commercial reach –
COPENHAGEN, Denmark, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...
- TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response -
Investors need to pay close attention to Ascendis Pharma (ASND) stock based on the movements in the options market lately.
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting –
COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...
Ascendis has a PDUFA date of June 25, 2021 for its lead indication. However, what makes this pre-market stage company so valuable is its TransCon platform.
Ascendis Pharma's (ASND) CEO Jan Mikkelsen on Q3 2020 Results - Earnings Call Transcript
– Event will provide an overview of how A s cendis is applying its TransCon ™ technology platform and its unique algorithm for product innovation to the therapeutic area of o ncology –
Shares of Ascendis Pharma (NASDAQ:ASND) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 365.52% over the past year to ($2.70), whi...
– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) f or TransCon TM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) –
Ascendis (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs,...
COPENHAGEN, Denmark, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs,...
COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, ...
COPENHAGEN, Denmark, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs,...
Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.
- Six-month data from PaTH Forward open-label extension support potential use of TransCon PTH as a hormone replacement therapy for adult hypoparathyroidism –
COPENHAGEN, Denmark, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical need...
– Introduces #Together4Growth to increase awareness of children’s growth disorders, including a four-question Growth Quiz to help parents identify signs and symptoms –
COPENHAGEN, Denmark, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical nee...
COPENHAGEN, Denmark, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical need...
Ascendis Pharma sees its Relative Strength Rating reach the 80-plus level. The post Stocks Showing Rising Market Leadership: Ascendis Pharma Earns 82 RS Rating appeared first on Investor's Business Daily.
COPENHAGEN, Denmark, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that uses its novel TransCon technologies to address unmet medical needs, announ...
– Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2021 –
COPENHAGEN, Denmark, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical need...
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorpo... [Read more...]
| Industry Biotechnology | IPO Date Jan 28, 2015 |
| CEO Jan Moeller Mikkelsen | Employees 482 |
| Stock Exchange NASDAQ | Ticker Symbol ASND |
Financial Performance
In 2020, ASND's revenue was 6.95 million, a decrease of -48.01% compared to the previous year's 13.38 million. Losses were -418.96 million, 92.2% more than in 2019.
Analyst Forecasts
According to 11 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is 195.40, which is an increase of 50.02% from the latest price.